Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bristol-Myers Squibb |
---|---|
Information provided by: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00036621 |
This clinical trial will assess whether BMS-275291 can be administered safely in combination with standard adjuvant therapy for early breast cancer and whether plasma concentrations at trough exceed a target minimum.
Condition | Intervention | Phase |
---|---|---|
Breast Cancer |
Drug: BMS-275291 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Systemic therapy is planned according to one of the following three regimens:
Adequate organ function as evidenced by:
Exclusion Criteria:
United States, Illinois | |
Local Institution | |
Chicago, Illinois, United States | |
United States, Indiana | |
Local Institution | |
Indianapolis, Indiana, United States | |
United States, Maryland | |
Local Institution | |
Baltimore, Maryland, United States | |
United States, New York | |
Local Institution | |
Bronx, New York, United States | |
United States, Ohio | |
Local Institution | |
Cincinnati, Ohio, United States | |
United States, Oregon | |
Local Institution | |
Portland, Oregon, United States | |
United States, Vermont | |
Local Institution | |
Burlington, Vermont, United States | |
United States, Washington | |
Local Institution | |
Vancouver, Washington, United States | |
United States, Wisconsin | |
Local Institution | |
Green Bay, Wisconsin, United States |
Study ID Numbers: | CA161-006 |
Study First Received: | May 11, 2002 |
Last Updated: | June 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00036621 |
Health Authority: | United States: Food and Drug Administration |
Skin Diseases Breast Neoplasms Breast Diseases |
Neoplasms Neoplasms by Site |